| CAS NO: | 188627-80-7 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Cas No. | 188627-80-7 |
| 别名 | 依替巴肽 |
| Canonical SMILES | O=C([C@H](CC1=CNC2=C1C=CC=C2)N3)N4[C@](CCC4)([H])C(N[C@H](C(N)=O)CSSCCC(N[C@@H](CCCCNC(N)=N)C(NCC(N[C@@H](CC(O)=O)C3=O)=O)=O)=O)=O |
| 分子式 | C35H49N11O9S2 |
| 分子量 | 832 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 14 mg/ml,Ethanol: 5 mg/ml,PBS (pH 7.2): 5 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Eptifibatide is a potent glycoprotein IIb/IIIa antagonist (GPIIb/IIIa; Kd= 120 nM) that inhibits platelet aggregation.1,2Eptifibatide prevents binding of the adhesion proteins fibrinogen and von Willebrand factor to GPIIb/IIIa on the surface of activated platelets to prevent aggregation and thrombus formation.3It inhibits ADP-induced citrated blood aggregation (IC50= 0.11-0.22 μg/ml)in vitroandin vivo(IC50= 52 μg/ml in porcine plasma).1,4Formulations containing eptifibatide have been used to reduce risk of thrombolysis in myocardial infarction in patients undergoing percutaneous coronary intervention.5 1.Harder, S., Klinkhardt, U., Graff, J., et al.In vitro dose response to different GPIIb/IIIa-antagonists: Inter-laboratory comparison of various platelet function testsThromb. Res.102(1)39-48(2001) 2.Moser, M., Bertram, U., Peter, K., et al.Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregatesJ. Cardiovasc. Pharmacol.41(4)586-592(2003) 3.Scarborough, R.M.Development of eptifibatideAm. Heart J.138(6 Pt 1)1093-1104(1999) 4.Ciborowski, M., and Tomasiak, M.The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood plateletsActa Pol. Pharm.66(3)235-242(2009) 5.Zhou, X., Wu, X., Sun, H., et al.Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysisJ. Evid. Based Med.10(2)136-144(2017) |
m.cnreagent.com